Exforge

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

valsartan, amlodipine (as amlodipine besilate)

Available from:

Novartis Europharm Limited

ATC code:

C09DB01

INN (International Name):

amlodipine, valsartan

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

Trattament ta 'ipertensjoni essenzjali. Exforge huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Product summary:

Revision: 31

Authorization status:

Awtorizzat

Authorization date:

2007-01-16

Patient Information leaflet

                                52
B. FULJETT TA’ TAGĦRIF
53
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
EXFORGE 5 MG/80 MG PILLOLI MIKSIJA B’RITA
EXFORGE 5 MG/160 MG PILLOLI MIKSIJA B’RITA
EXFORGE 10 MG/160 MG PILLOLI MIKSIJA B’RITA
amlodipine/valsartan
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li m’huwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Exforge u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Exforge
3.
Kif għandek tieħu Exforge
4.
Effetti sekondarji possibbli
5.
Kif taħżen Exforge
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU EXFORGE U GЋALXIEX JINTUŻA
Il-pilloli Exforge fihom żewġ sustanzi li jissejjħu amlodipine u
valsartan. Dawn iż-żewġ sustanzi t-
tnejn li huma jgħinu sabiex tkun kontrollata l-pressjoni għolja
tad-demm.
-
Amlodipine huwa membru ta’ grupp ta’ sustanzi li jissejjħu
“imblokkaturi tal-kanali ta’
calcium”. Amlodipine jwaqqaf lil calcium milli jidħol fill-ħajt
ta’ ġewwa tal-vini u dan ma
jħallix lill-vini tad-demm jingħafsu.
-
Valsartan huwa membru ta’ grupp ta’ sustanzi li jissejħu
“antagonisti tar-riċetturi ta’ angiotensin
II”. Angiotensin II jiġi iffurmat mill-ġisem u jġiegħel il-vini
jingħafsu, u għalhekk jgħolli l-
pressjoni tad-demm. Valsartan jaħdem billi jimblokka l-effett ta’
angiotensin II.
Dan ifisser li dawn iż-żewġ sustanzi jgħinu biex iwaqqfu lill-vini
tad-demm milli jingħafsu. B’hekk,
il-vini jintreħew u l-pressjoni tad-demm titbaxxa.
Exforge ji
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Exforge 5 mg/80 mg pilloli miksija b’rita
Exforge 5 mg/160 mg pilloli miksija b’rita
Exforge 10 mg/160 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
_ _
Exforge 5 mg/80 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 5 mg ta’ amlodipine (bħala
amlodipine besylate) u 80 mg valsartan.
Exforge 5 mg/160 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 5 mg ta’ amlodipine (bħala
amlodipine besylate) u 160 mg valsartan.
Exforge 10 mg/160 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 10 mg ta’ amlodipine (bħala
amlodipine besylate) u 160 mg valsartan.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita
Exforge 5 mg/80 mg pilloli miksija b’rita
Pillola safra skura, tonda miksija b’rita b’xifer imżerżaq,
ittimbrata “NVR” fuq naħa u “NV” fuq l-
oħra. Daqs approssimattiv: dijametru 8.20 mm.
Exforge 5 mg/160 mg pilloli miksija b’rita
Pillola safra skura, ovali miksija b’rita, ittimbrata “NVR” fuq
naħa u “ECE” fuq l-oħra. Daqs
approssimattiv: 14.2 mm (tul) x 5.7 mm (wisa’).
Exforge 10 mg/160 mg pilloli miksija b’rita
Pillola safra ċara, ovali miksija b’rita, ittimbrata “NVR” fuq
naħa u “UIC” fuq l-oħra. Daqs
approssimattiv: 14.2 mm (tul) x 5.7 mm (wisa’).
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kura għall-pressjoni li tkun għolja b’mod naturali.
Exforge hu indikat għall-użu fl-adulti li jkollhom pressjoni għolja
li ma tkunx kontrollata b’terapija ta’
amlodipine jew valsartan mogħtija waħidhom.
3
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża ta’ Exforge rakkomandata hija pillola waħda kuljum.
Exforge 5 mg/80 mg jista’ jingħata lill-pazjenti li ma jkollhomx
pressjoni kontrollata tajjeb
b’amlodipine 5 mg jew valsartan 80 mg waħidhom.
Exforge 5 mg/160 mg jista’ jingħata lill-pazjenti li ma jkol
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-11-2022
Public Assessment Report Public Assessment Report Bulgarian 05-08-2015
Patient Information leaflet Patient Information leaflet Spanish 11-11-2022
Public Assessment Report Public Assessment Report Spanish 05-08-2015
Patient Information leaflet Patient Information leaflet Czech 11-11-2022
Public Assessment Report Public Assessment Report Czech 05-08-2015
Patient Information leaflet Patient Information leaflet Danish 11-11-2022
Public Assessment Report Public Assessment Report Danish 05-08-2015
Patient Information leaflet Patient Information leaflet German 11-11-2022
Public Assessment Report Public Assessment Report German 05-08-2015
Patient Information leaflet Patient Information leaflet Estonian 11-11-2022
Public Assessment Report Public Assessment Report Estonian 05-08-2015
Patient Information leaflet Patient Information leaflet Greek 11-11-2022
Public Assessment Report Public Assessment Report Greek 05-08-2015
Patient Information leaflet Patient Information leaflet English 11-11-2022
Public Assessment Report Public Assessment Report English 05-08-2015
Patient Information leaflet Patient Information leaflet French 11-11-2022
Public Assessment Report Public Assessment Report French 05-08-2015
Patient Information leaflet Patient Information leaflet Italian 11-11-2022
Public Assessment Report Public Assessment Report Italian 05-08-2015
Patient Information leaflet Patient Information leaflet Latvian 11-11-2022
Public Assessment Report Public Assessment Report Latvian 05-08-2015
Patient Information leaflet Patient Information leaflet Lithuanian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-11-2022
Public Assessment Report Public Assessment Report Lithuanian 05-08-2015
Patient Information leaflet Patient Information leaflet Hungarian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 11-11-2022
Public Assessment Report Public Assessment Report Hungarian 05-08-2015
Patient Information leaflet Patient Information leaflet Dutch 11-11-2022
Public Assessment Report Public Assessment Report Dutch 05-08-2015
Patient Information leaflet Patient Information leaflet Polish 11-11-2022
Public Assessment Report Public Assessment Report Polish 05-08-2015
Patient Information leaflet Patient Information leaflet Portuguese 11-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 11-11-2022
Public Assessment Report Public Assessment Report Portuguese 05-08-2015
Patient Information leaflet Patient Information leaflet Romanian 11-11-2022
Public Assessment Report Public Assessment Report Romanian 05-08-2015
Patient Information leaflet Patient Information leaflet Slovak 11-11-2022
Public Assessment Report Public Assessment Report Slovak 05-08-2015
Patient Information leaflet Patient Information leaflet Slovenian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 11-11-2022
Public Assessment Report Public Assessment Report Slovenian 05-08-2015
Patient Information leaflet Patient Information leaflet Finnish 11-11-2022
Public Assessment Report Public Assessment Report Finnish 05-08-2015
Patient Information leaflet Patient Information leaflet Swedish 11-11-2022
Public Assessment Report Public Assessment Report Swedish 05-08-2015
Patient Information leaflet Patient Information leaflet Norwegian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 11-11-2022
Patient Information leaflet Patient Information leaflet Icelandic 11-11-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 11-11-2022
Patient Information leaflet Patient Information leaflet Croatian 11-11-2022
Public Assessment Report Public Assessment Report Croatian 05-08-2015

Search alerts related to this product

View documents history